Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

WITHDRAWN
Study of CAD-1883 for Spinocerebellar Ataxia
Description

This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety, tolerability, and efficacy of CAD-1883 in the SCA patient population.

ACTIVE_NOT_RECRUITING
Troriluzole in Adult Participants With Spinocerebellar Ataxia
Description

The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

COMPLETED
Trial in Adult Subjects With Spinocerebellar Ataxia
Description

The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA).